Eidos Therapeutics

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company focused on developing novel therapies for RAS and PI3K-driven cancers. Driven by the mission to accelerate scientific and medical breakthroughs, BBOT aims to deliver well-tolerated and effective medicines to patients battling the deadliest cancers. Their research leverages innovative chemical biology approaches to inhibit various KRAS mutations in both the "on" and "off" states, as well as bypass mechanisms that exploit PI3K signaling. This targeted approach promises to transform the treatment of these prevalent cancers.

BBOT currently has three primary programs in development. BBO-8520, a direct inhibitor of KRASG12C, is currently in Phase 1 clinical trials. BBO-10203, a PI3Kα:RAS breaker, is expected to enter clinical trials later in 2024, while BBO-11818, a pan-KRAS inhibitor, is anticipated to enter clinical trials in early 2025. BBOT's leadership team consists of world-renowned experts in the field of RAS and PI3K signaling pathways, along with a robust network of investors, including Cormorant Asset Management and Omega Funds.

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company dedicated to developing novel small molecule therapies that target RAS and PI3K pathway malignancies. The company's mission is to accelerate scientific and medical breakthroughs by uncovering innovative approaches to these complex pathways, translating findings into clinical applications, and delivering well-tolerated medicines with greater efficacy and safety to patients battling the deadliest cancers. BBOT is committed to redefining what's possible in precision oncology to improve the lives of those affected by RAS-dependent cancers.

Eidos Therapeutics, now BridgeBio Oncology Therapeutics (BBOT), promotes a collaborative and innovative culture that values expertise and scientific excellence. The company is focused on accelerating breakthroughs in precision oncology and fostering a culture of trust and experience, bringing together world-leading RAS cancer biologists, medicinal chemists, and drug developers to create novel, well-tolerated medicines that maximize patient benefit.

Eidos Therapeutics (BBOT) demonstrates its commitment to diversity, equity, and inclusion through its diverse leadership team and a focus on building a collaborative environment that values different perspectives and experiences. This is reflected in their recruitment efforts, promotion practices, and commitment to creating an inclusive workplace where all employees feel valued, respected, and empowered to contribute to the company's mission of developing life-saving therapies.